Original Research

Published on 29 Aug 2024

Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors

in Pharmacology of Anti-Cancer Drugs

Arba Karcini
Nicole R. Mercier
Iulia M. Lazar

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1413818

911 views
1 citation

Systematic Review

Published on 29 Aug 2024

The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis

in Pharmacology of Anti-Cancer Drugs

Siyu Tian
Min Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1466156

1,165 views

Original Research

Published on 28 Aug 2024

Predicting the efficiency of chidamide in patients with angioimmunoblastic T-cell lymphoma using machine learning algorithm

in Pharmacology of Anti-Cancer Drugs

Chunlan Zhang
Juan Xu
Mingyu Gu
Yun Tang
Wenjiao Tang
Jie Wang
Qinyu Liu
Yunfan Yang
Xushu Zhong
Caigang Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1435284

678 views

Original Research

Published on 28 Aug 2024

Network-based prediction of anti-cancer drug combinations

in Pharmacology of Anti-Cancer Drugs

Jue Jiang
Xuxu Wei
YuKang Lu
Simin Li
Xue Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1418902

1,043 views

Original Research

Published on 27 Aug 2024

Identification of novel PHGDH inhibitors based on computational investigation: an all-in-one combination strategy to develop potential anti-cancer candidates

in Pharmacology of Anti-Cancer Drugs

Yujing Xu
Zhe Yang
Jinrong Yang
Chunchun Gan
Nan Qin
Xiaopeng Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1405350

911 views

Review

Published on 27 Aug 2024

Dual roles of inflammatory programmed cell death in cancer: insights into pyroptosis and necroptosis

in Pharmacology of Anti-Cancer Drugs

Shuai Wang
Huanhuan He
Lailiang Qu
Qianhe Shen
Yihang Dai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1446486

857 views

Review

Published on 26 Aug 2024

DNA damage response-related ncRNAs as regulators of therapy resistance in cancer

in Pharmacology of Anti-Cancer Drugs

Ziru Gao
Xinchi Luan
Xuezhe Wang
Tianyue Han
Xiaoyuan Li
Zeyang Li
Peifeng Li
Zhixia Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1390300

870 views

Original Research

Published on 23 Aug 2024

Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database

in Pharmacology of Anti-Cancer Drugs

Yusen Zhou
Peng Jia
Yuting Fang
Wei Zhu
Yong Gong
Tianyu Fan
Jiangliu Yin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1437436

1,126 views

Review

Published on 23 Aug 2024

Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management

in Pharmacology of Anti-Cancer Drugs

Vikas Sharma
Anis Ahmad Chaudhary
Sweta Bawari
Saurabh Gupta
Richa Mishra
Salah-Ud-Din Khan
Mohamed A. M. Ali
Mohammad Shahid
Saurabh Srivastava
Devvrat Verma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1414790

1,380 views

Original Research

Published on 22 Aug 2024

The role of the miR-30a-5p/BCL2L11 pathway in rosmarinic acid-induced apoptosis in MDA-MB-231-derived breast cancer stem-like cells

in Pharmacology of Anti-Cancer Drugs

Wei Wang
Yuefen Zhang
Xiaomin Huang
Dan Li
Qi Lin
Hailin Zhuang
Hong Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1445034

858 views

Original Research

Published on 21 Aug 2024

Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC

in Pharmacology of Anti-Cancer Drugs

Junxia Ma
Jinggang Mo
Yifu Feng
Liezhi Wang
Hao Jiang
Junmin Li
Chong Jin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1450847

798 views

Original Research

Published on 21 Aug 2024

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database

in Pharmacology of Anti-Cancer Drugs

Yilun Li
Xiaolu Yang
Li Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1345671

923 views

Original Research

Published on 21 Aug 2024

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023)

in Pharmacology of Anti-Cancer Drugs

Jing Shi
Xinya Liu
Yun Jiang
Mengjiao Gao
Jian Yu
Yuanming Zhang
Li Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1434231

1,100 views

Original Research

Published on 21 Aug 2024

Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC

in Pharmacology of Anti-Cancer Drugs

Li-xin Du
Guo-li Sheng
An-da Shi
Kang-shuai Li
Zeng-li Liu
Yong-chang Tang
Yi Liu
Zong-li Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1426912

708 views

Original Research

Published on 20 Aug 2024

Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin

in Pharmacology of Anti-Cancer Drugs

S. Ceddia
C. E. Onesti
S. Vari
A. Torchia
A. Cosimati
F. Riva
M. T. Maccallini
M. Cerro
G. Benvenuti
M. Russillo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1411707

708 views

Original Research

Published on 20 Aug 2024

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)

in Pharmacology of Anti-Cancer Drugs

KaiLi Mao
Ping Chen
HuaYu Sun
SongYang Zhong
HongLiang Zheng
LuYao Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1425617

1,901 views

Navigation group

Articles

Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors

The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis

Predicting the efficiency of chidamide in patients with angioimmunoblastic T-cell lymphoma using machine learning algorithm

Network-based prediction of anti-cancer drug combinations

Identification of novel PHGDH inhibitors based on computational investigation: an all-in-one combination strategy to develop potential anti-cancer candidates

Dual roles of inflammatory programmed cell death in cancer: insights into pyroptosis and necroptosis

DNA damage response-related ncRNAs as regulators of therapy resistance in cancer

Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database

Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management

The role of the miR-30a-5p/BCL2L11 pathway in rosmarinic acid-induced apoptosis in MDA-MB-231-derived breast cancer stem-like cells

Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023)

Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC

Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)